• Jul. 04, 2018 (PDF/86KB)R&D

  Sumitomo Dainippon Pharma Submits New Drug Application for Thiotepa in Japan for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors

• Jul. 02, 2018 (PDF/126KB)Products

  Sumitomo Dainippon Pharma Obtains Approval in Japan for TRERIEF, a therapeutic agent for Parkinson's disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies

• Jun. 28, 2018 (PDF/100KB)CSR

  Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan

• Jun. 25, 2018 (PDF/620KB)R&D

  Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277) at the 2nd Pan American Parkinson's Disease and Movement Disorders Congress

• Jun. 15, 2018 (PDF/127KB)Corporate

  Sumitomo Dainippon Pharma announces personnel changes

more